PDCD1 and intrahepatic cholangiocarcinoma: In patients receiving anti-PD1 treatment, the ORR was 31.1% (95% CI: 21.8%–41.7%) and DCR was 85.6% (95% CI: 76.6%–92.1%) for the ICC group, with 2 complete response (CR), 26 partial response (PR), 49 stable disease (SD), and 13 progressive disease (PD) instances.